The estimated Net Worth of Bay Ltd. Nomis is at least $2.52 mil millones dollars as of 9 March 2021. Bay Nomis owns over 235,238 units of Humanigen stock worth over $194,247 and over the last 4 years Bay sold HGEN stock worth over $2,517,804,576.
Sign up
Bay Nomis HGEN stock SEC Form 4 insiders trading
Bay has made over 18 trades of the Humanigen stock since 2020, according to the Form 4 filled with the SEC. Most recently Bay sold 235,238 units of HGEN stock worth $3,883,779 on 9 March 2021.
The largest trade Bay's ever made was selling 300,000 units of Humanigen stock on 17 July 2020 worth over $1,500,000. On average, Bay trades about 69,263 units every 15 days since 2020. As of 9 March 2021 Bay still owns at least 5,380,799 units of Humanigen stock.
You can see the complete history of Bay Nomis stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Bay Nomis's mailing address?
Bay's mailing address filed with the SEC is 45 Reid Street, Hamilton, Bermuda.
Insiders trading at Humanigen
Over the last 5 years, insiders at Humanigen have traded over $2,588,252,690 worth of Humanigen stock and bought 2,107,496 units worth $5,417,461 . The most active insiders traders include Dale Cheval Holdings, Ltd.B..., Dale Black Horse Capital Ma... y Bay Ltd. Nomis. On average, Humanigen executives and independent directors trade stock every 34 days with the average trade being worth of $7,693. The most recent stock trade was executed by Dale Black Horse Capital Lp... on 18 October 2023, trading 386,350 units of HGEN stock currently worth $3,864.
What does Humanigen do?
Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of anti-inflammatory immunology and immuno-oncology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which has completed Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that is in Phase II clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which has completed pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
What does Humanigen's logo look like?
Complete history of Bay Nomis stock trades at Humanigen
Humanigen executives and stock owners
Humanigen executives and other stock owners filed with the SEC include:
-
Dr. Cameron Durrant M.B.A., M.D., MBA,
Chairman & CEO -
Timothy E. Morris CPA, CPA,
CFO & COO -
Timothy E. Morris CPA,
CFO & COO -
Dr. Dale Chappell M.B.A., M.D., MBA,
Chief Scientific Officer & Director -
Dr. Adrian Kilcoyne M.B.A., M.D., M.P.H.,
Chief Medical Officer -
Edward P. Jordan M.B.A.,
Chief Commercial Officer -
Robert Atwill M.B.A.,
Head of Asia-Pacific Region -
Dr. Omar Ahmed Pharm.D.,
Sr. VP of Clinical, Medical & Scientific Affairs -
Dr. Tarek Sahmoud M.D., Ph.D.,
Chief Medical Officer -
Kenneth Eugene Trbovich C.F.A.,
Sr. VP of Investor Relations -
Bay Ltd. Nomis,
10% owner -
Dale Chappell,
Chief Scientific Officer -
Cheryl Buxton,
-
Dale Cheval Holdings, Ltd.B...,
-
Ronald Barliant,
-
Edward P. Jordan,
Chief Commercial Officer -
Cameron Durrant,
Chief Executive Officer -
Rainer J. Boehm,
-
Dale Black Horse Capital Ma...,
Chief Scientific Officer -
Yili Kevin Xie,
-
John Hohneker,
-
Dale Cheval Holdings, Ltd.B...,
Chief Scientific Officer -
Timothy E Morris,
COO and CFO -
Dale Black Horse Capital Lp...,
Chief Scientific Officer -
Dale Black Horse Capital Lp...,
Chief Scientific Officer